HLS Therapeutics to Present at Stifel GMP's Future of Healthcare Conference

TORONTO, Dec. 1, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer, will present at Stifel GMP's 2^nd Annual Future of Healthcare Conference on Wednesday December 8, 2021 at 10:30 a.m. Eastern Standard Time. The conference will be held in a virtual meeting format.

An audio webcast of the Company's presentation will be available at: https://wsw.com/webcast/stifel62/register.aspx?conf=stifel62&page=hls.to&url=https://wsw.com/webcast/stifel62/hls.to/2364360   

ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

Dave Mason, Investor Relations, HLS Therapeutics Inc., [phone], [email protected]